Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8895057 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(5 years from now) | |
US9011906 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(5 years from now) | |
US9011905 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(5 years from now) | |
US8895058 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(5 years from now) | |
US8580298 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
May, 2029
(5 years from now) | |
US8580299 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jun 24, 2025 |
Market Authorisation Date: 17 July, 2012
Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
22
United States
6
Japan
4
China
3
Korea, Republic of
2
Canada
2
Mexico
2
Brazil
2
South Africa
2
Australia
2
Israel
2
Chile
2
European Union
1
Cyprus
1
Denmark
1
Portugal
1
Spain
1
Hong Kong
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic